Equity Brief · Healthcare2026-05-20
BAYN.DE·Healthcare

Bayer AG NA

I · Analiza AI

Pe scurt

Bayer makes prescription medicines for heart disease, women's health, cancer, and blood disorders; sells consumer brands like Midol and Aspirin; and provides seeds, pesticides, and digital farming tools to agriculture customers worldwide [Yahoo Finance]. The Crop Science division is the largest profit contributor, generating nearly half of total revenue [Simply Wall St].

Bayer is a 161-year-old German life sciences giant operating three major divisions: prescription drugs (Pharmaceuticals), over-the-counter health products (Consumer Health), and agricultural seeds and crop chemicals (Crop Science) [Yahoo Finance]. The company currently reports a €2.2 billion net loss on €45.6 billion in revenue, but recent news signals potential recovery through two FDA priority-review drugs in stroke prevention and lung cancer [Yahoo Finance]. Bayer also faces ongoing environmental liabilities, including a recent $133 million settlement for PCB contamination cleanup [Seeking Alpha].

Bayer is currently unprofitable with moderate debt levels, but maintains strong gross margins and positive free cash flow [Yahoo Finance].

Pe scurt AI analysisÎncredere 7/10

Scor Sentinellis

4.2/10

Moderate concerns

Capitalizare bursieră

EUR 37.8B

Venituri (12 luni)

EUR 45.6B

II · Știri recente

Ce a mișcat prețul

6 stories · ranked by relevance

  • macro2026-05-20

    BAYRY or RHHBY: Which Is the Better Value Stock Right Now?

    Zacks

  • macro2026-05-20

    Should FDA Priority Review for HYRNUO’s First-Line Lung Cancer Use Require Action From Bayer (XTRA:BAYN) Investors?

    Yahoo Finance

  • macro2026-05-19

    Bayer Gets FDA Priority Review for Asundexian NDA in Stroke Prevention

    Yahoo Finance

  • macro2026-05-19

    Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack

    Yahoo Finance

  • macro2026-05-19

    FDA Grants Priority Tag to Bayer's Oncology Drug for First-Line NSCLC

    Yahoo Finance

  • macro2026-05-17

    Assessing Bayer (XTRA:BAYN) Valuation After Mixed Share Performance And Profit Recovery Hopes

    Simply Wall St

Premium · gratuit cu orice cont

Bayer reported a €2.2 billion net loss for the most recent fiscal year despite €45.6 billion in revenue, and the company remains unprofitable with a negative net margin of -7.9% [Yahoo Finance]

1 din 5 riscuri din acest raport

Riscuri

5

Oportunități

5

Semnale de alarmă

3

Conducere

10

Încă 22 de constatări în raportul complet — gratuit cu orice cont.

Deblochează analiza completă Bayer AG NA

Fă-ți un cont gratuit ca să vezi raportul complet generat de AI, cu surse citate în text.

  • 5 riscuri, 5 oportunități și 3 semnale de alarmă — fiecare cu sursa lui
  • Peste 100 de indicatori financiari, cu grafice și comparații
  • Rezumate complete ale știrilor, cu linkuri către surse
  • Echipa de conducere și remunerația
  • Export PDF pentru citit offline
Deblochează 13 constatări3 rapoarte gratuite · fără card

III · Companii similare

Ai putea citi și

Same sector · Healthcare or comparable health

Vrei compania asta pe lista ta?

Read three companies free. Fără card.

Primești 3 rapoarte gratuite